Imatinib is a type of protein tyrosine kinase inhibitor which inhibits the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome i.e. the BCR-ABL tyrosine kinase, abnormality in CML patient. The aim of the study is to assess the response of imatinib in CML patients and to observe resistance to imatinib. Study was performed at Ahmedabad, Gujarat, India. Dose of 400, 600, 800 mg of Imatinib was found to be prescribed to all patients during the study. Comparison of laboratory parameters and PCR data were done after measurement by RT-PCR method. Total 256 patients with CML were enrolled in the study. 196 patients had completed study as per protocol. 38 patients were newly diagnosed whereas 158 patients were already diagnosed with CML. 89.29% (n = 175) of patients achieved complete haematological response, Complete MolR were achieved in n = 41 at 6th months, n = 1 at 12th month and 18th month and no patient was found with none CyR out of 196 patients; no patient were found with minimal CyR at 6th month, 2 patient were at 12th month and 3 patients were at 18th month. Mean PCR value (BCR-ABL/ABL ratio) in patient was found 0.245±1.16 at Day 0, 0.824±1.51 at 6th month, 4.086±9.58 at 12th month and 6.713±11.32 at 18th month visit. In conclusion, it was observed that resistance to imatinib might be developed within an average time of 12 months in the patients due to which survival rate was drastically reduced.
Cite this article:
Ankit Darji, Praful Bharadia. Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients. Research Journal of Pharmacy and Technology. 2021; 14(8):4092-0. doi: 10.52711/0974-360X.2021.00709
Ankit Darji, Praful Bharadia. Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients. Research Journal of Pharmacy and Technology. 2021; 14(8):4092-0. doi: 10.52711/0974-360X.2021.00709 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-15
1. Knowles MA, Selby PJ, Introduction to Cellular and Molecular Biology of Cancer, 4th edn, Oxford University Press, 2005, pp 15-289.
3. Druker BJ, Talpaz M, Resta DJ, et al. “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.” N. Engl. J. Med. 2001, 344, 31- 37.
4. Kantarjian H, Sawyers C, Hochhaus A, et al, “ Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.” N. Engl. J. Med. 2002, 346, 645-652.
8. Gschwind H, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, et al, “ Metabolism and disposition of imatinib mesylate in healthy volunteers.” DMD. 2005, 33, 1503–1512.
9. Anderson PO, Knoben JE, Troutman WG, Handbook of Clinical Drug Data, 10th edn, McGraw Hill Medical Publishing Division, 2002, pp 266-267.
10. Gschwind H, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P,et al, “ Metabolism and disposition of imatinib mesylate in healthy volunteers.” DMD. 2005, 33, 1503–1512.
11. Tejani S, Sanoski CA, Davis’s Pocket Clinical Drug Reference, 1st edn, F A Davis Company, 2009, pp 141-142.
12. Deininger M, Buchdunger E, Druker BJ, “The development of imatinib as a therapeutic agent for chronic myeloid leukemia.” Blood. 2005, 105(7), 2640-2653.
13. K. Patton and D.C. Borsoff, “Adverse Drug Reactions”, Anaesthesia, 2018, 73 (1), 76–84.
14. Alan H Turner, Marilyn J Pike and Maureen A Francis, “Haematology what does your blood test mean?, RMIT university”, Edited by: Indu Singh 2008, School of Medical Science 2008, 1-12.
15. Trevor J. Whitbread, “Clinical Biochemistry”, Abbey Veterinary Services, MSD and the MSD Veterinary Manual, dated 15 Aug 2017.
16. R Karthikeyan, B Thangabalan, A Elphine Prabahar, P Vijayaraj Kumar. New Spectrophotometric Methods for the Determination of Imatinib in Bulk Drug and in Pharmaceutical Formulations. Research J. Pharm. and Tech.2 (3): July-Sept. 2009,;Page 578-581.
17. S.P. Senthil, K.L. Senthilkumar, Sadasiva Reddy Chandi, R.P. Ezhilmuthu, M.M. Saravanan, Nagesh R. Sandu. Formulation and Evaluation of Imatinib Mesylate Microspheres by Chemical Crosslinking Method. Research J. Pharm. and Tech. 5(7): July 2012; Page 934-937.
18. Muhammed A. H. Aldabagh, Sahar S. Karieb, Ali N. Yassen, Saddam H. Jaber, Mohammed S. Abbas, Ali M. Jawad. Reading of Immune picture in Chronic Myeloid Leukemia in Iraqi Patients. Research J. Pharm. and Tech. 2019; 12(4): 1910-1914.
19. Vadivelan. R, Triveni Jasti, Punitha Nanjundan, Gautam Adhikari, Arun. T. Beneficial effects of Tryosine kinase Inhibitor Imatinib on Striatal Motor behaviour in 6-OHDA lesioned rat model. Research J. Pharm. and Tech 2019; 12(8): 3745-3750.
20. Kiranmai Gudimetla, Orsu Prabhakar, Abhisek Pal. Review on Pathophysiological and Pharmacotherapeutic approach on Chronic Myeloid Leukemia. Research J. Pharm. and Tech 2020; 13(6): 2971-2976.
21. Arti Mohan, G. Sangeetha. Formulation and Evaluation of Immediate Release Film Coated Tablets of An Anticancer Drug (Dasatinib). Research J. Pharm. and Tech 2019; 12(2): 729-734.
22. Mohammed Khudair Hasan, Mowafaq Mohammed Ghareeb, Bassam Francis Mate, Qutaiba Ahmed Ibrahim Al Khames Aga. Clinical adverse effects of Chemotherapy protocolusing 6- Mercaptopurine in Iraqi patients with Acute Lymphocytic Leukemia during Maintenance Phase. Research J. Pharm. and Tech. 2019; 12(12): 5757-5764.
23. Saranya M, Punnagai K, Darling Chellathai David, Anusha D. Evaluation of Anticancer Effects of Vasopressin Receptor blocker in Colon Cancer – An In vitro Study. Research J. Pharm. and Tech. 2020; 13(1): 77-80.
24. Shivanika Mani, Brindha Devi P. Study on Genetically Engineered Vesicular Stomatitis Virus for the Application of Treating Malignant Diseases using Gene Therapy. Research J. Pharm. and Tech. 2019; 12(11): 5371-5378.
25. Chitra P, Ebenezer Jebarani M R, Kavipriya P, Srilatha K, Sumathi M, Lakshmi S. Detection of AML in Blood Microscopic Images using Local Binary Pattern and Supervised Classifier. Research J. Pharm. and Tech. 2019; 12(4): 1717-1720.